A review of pramipexole and its clinical utility in Parkinson’s disease

REFERENCES

• DE RIJK MC, LAUNER LJ, BERGER K et al.: Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 54(11, Suppl. 5):S21–S23.
   Google Scholar
• BOWER JH, MARAGANORE DM, MCDONNELL SK, ROCCA WA: Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology (1999) 52(6):1214–1220.
   PubMed Web of Science ®Google Scholar
• LING LH, AHLSKOG JE, MUNGER TM, LIMPER AT-I, OH JK: Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Chu. Proc. (1999) 74(4):371–375.
   PubMed Web of Science ®Google Scholar
• SHAUNAK S, WILKINS A, PILLING JB, DICK DJ: Pericardial, retroperitoneal and pleural fibrosis induced by pergolide. Neural Neurosurg. Psych. (1999) 66(1):79–81.
   PubMed Web of Science ®Google Scholar
• JIMENEZ-JIMENEZ FJ, LOPEZ- ALVAREZ J, SANCHEZ-CHAPADO Met al.: Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Chit. Neurapharmacal (1995) 18(3):277–279.
   Google Scholar
• TODMAN DH, OLIVER WA, EDWARDS RL: Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Chu. Exp. Neural (1990) 27:79–82.
   Google Scholar
• WARD CD, THOMPSON J, HUMBY MD: Pleuropulmonary and retroperitoneal fibrosis associated with bromocriptine treatment. j. Neural Neurosurg. Psych. (1987) 50(12):1706–1707.
   PubMed Web of Science ®Google Scholar
• THE PARKINSON STUDY GROUP: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl. I Med (1993) 328(3):176–183.
   PubMed Web of Science ®Google Scholar
• FAHN S: Controversies in the therapy of Parkinson's disease. Adv. Neural. (1996) 69:477–486.
   PubMedGoogle Scholar
• SCHNEIDER E: DATATOP-study: significance of its results in the treatment of Parkinson's disease. j. Neural. Tatum. Suppl. (1995) 46:391–397.
   PubMedGoogle Scholar
• THE PARKINSON STUDY GROUP: Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch. Neural (1995) 52(3):237–245.
   PubMedGoogle Scholar
• RASCOL 0: Medical treatment of levodopa-induced dyskinesias. Ann. Neural (2000) 47(4, Suppl. 1):5179–5188.
   Google Scholar
• DANIELCZYK W: Twenty-five years of amantadine therapy in Parkinson's disease. j. Neural. Transm. Suppl. (1995) 46:399–405.
   PubMedGoogle Scholar
• OBESO JA, RODRIGUEZ-OROZ MC, CHANA P, LERA G, RODRIGUEZ M, OLANOW CW: The evolution and origin of motor complications in Parkinson's disease. Neurology (2000) 55(11, Suppl. 4):S13–S20.
   Google Scholar
• SCHRAG A,QUINN N: Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain (2000) 123(11):2297–2305.
   Google Scholar
• REARDON KA, SHIFF M, KEMPSTER PA: Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years. Mov. Disord. (1999) 14(4):605–611.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: Pramipexole vs. levodopa as initial treatment for Parkinson's disease. JAMA (2000) 284:1931-1938. •• ••The only study systematically evaluating pramipexole versuslevodopa as initial therapy in PD.
   Google Scholar
• RASCOL 0, BROOKS DJ, KORCZYN AD et al.: A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa. N Engl. J. Med (2000) 342:1484–1491.
   Google Scholar
• RINNE UK, BRACCO F, CHOUZA C et al.: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa-controlled trial. PKD5009 Collaborative Study Group. Drugs (1998) 1:23–30.
   Google Scholar
• POEWE W: Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology (1998) 51(2, Suppl. 2):521–524.
   Google Scholar
• 2001 Drug Topics Red Book. Medical Economics Data Company, Montvale, New Jersey, USA (2001).
   Google Scholar
• PIERCEY MF: Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Neurapharmacal. (1998) 21(3):141–151. •A systematic review of the pharmacology and pharmacoldrietics of pramipexole.
   Google Scholar
• OHNMACHT U, TRANKLE C, GMEINER P: PH1Pramipexole: a selective radioligand for the high affinity dopamine D2 receptor in bovine striatal membranes. Pharmazie (1999) 54:294–297.
   PubMed Web of Science ®Google Scholar
• LANGE KW: Clinical pharmacology of dopamine agonists in Parkinson's disease. Pharm. (1998) 13(5):381–389.
   Google Scholar
• PIERCEY MF, HOFFMAN WE, SMITH MW, HYSLOP DK: Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur. I Pharmacy]. (1996) 312(1):35–44.
   PubMed Web of Science ®Google Scholar
• HUBBLE JP: Pre-clinical studies of pramipexole: clinical relevance. Eur. Neural. (2000) 7\(Suppl. 1):15–20. ••An excellent review of predinical studies ofpramipexole, its pharmacology and the potential human utility of the drug.
   Google Scholar
• COLDWELL MC, BOYFIELD I, BROWN T, HAGAN JJ, MIDDLEMISS DN: Comparison of the functional potencies of ropinerole and other dopamine receptors agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacal. (1999) 127:1696–1702.
   Google Scholar
• CAMACHO-OCHOA M, WALKER EL, EVANS DL, PIERCEY MF: Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist. Neurosci. Lett. (1995) 196(1-2):97–100.
   PubMed Web of Science ®Google Scholar
• CORRIGAN MH, DENAHAN AQ, WRIGHT CE, RAGUAL RJ, EVANS DL: Comparison of pramipexole, fluoxetine and placebo in patients with major depression. Depress. Anxiety (2000) 11(2):58–65.
   PubMed Web of Science ®Google Scholar
• MIERAU J, SCHNEIDER FJ, ENSINGER HA, CHIO CL, LAJINESS ME, HUFF RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur. Pharmacal. (1995) 290(1):29–36.
   PubMed Web of Science ®Google Scholar
• SAUTEL F, GRIFFON N, LEVESQUE D, PILON C, SCHWARTZ J, SOKOLOFF P: A functional test identifies dopamine agoinsts selective for D3 versus D2 receptors. (1995) 6:329–332.
   Google Scholar
• MIERAU J, SCHINGNITZ G: Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur. Pharmacal. (1992) 215(2-3):161–170.
   PubMed Web of Science ®Google Scholar
• DOMINO EF, NI L, ZANG H, KOHNO Y, SASA M: Effects of pramipexole on contraversive rotation and functional motor impairments in 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine-induced chronic hemiparkinsonian monkeys. J. Pharmacal. Exp. Ther. (1998) 287(3):983–987.
   PubMed Web of Science ®Google Scholar
• LORENC-KOCI E,WOLFARTH S: Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. Eur. Pharmacy]. (1999) 385(1):39–46.
   PubMed Web of Science ®Google Scholar
• CARTER AJ, MULLER RE: Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur. Pharmacal. (1991) 200(1):65–72.
   PubMed Web of Science ®Google Scholar
• SVENSSON K, CARLSSON A, HUFF RM, KLING-PETERSEN T, WATERS N: Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur. j Pharmacy]. (1994) 263(3):235–243.
   PubMed Web of Science ®Google Scholar
• WATTS RL: The role of dopamine agonists in early Parkinson's disease. Neurology (1997) 49\(Suppl. 1):534–548.
   Google Scholar
• WRIGHT CE, SISSON TL, ICHHPURANI AK, PETERS GR: Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J. Clin. Pharmacy]. (1997) 37:520–525.
   PubMed Web of Science ®Google Scholar
• HUBBLE JP, KOLLER WC, CUTLER NRet al.: Pramipexole in patients with early parkinson's disease. Clin Neurapharmacal (1995) 18(4):338–347.
   Google Scholar
• PARKINSON STUDY GROUP: Safety and efficacy of pramipexole in early Parkinson's disease: a randomised dose-ranging study. JAMA (1997) 278(2):125–130.
   PubMed Web of Science ®Google Scholar
• SHANNON KM, BENNETT JPJ, FRIEDMAN JH: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology (1997) 49(3):724–728. Erratum in Neurology (1998) 50(3):838. •A large, well designed study evaluating the efficacy and tolerability of pramipexole monotherapy in early PD.
   Google Scholar
• LIEBERMAN A, RANHOSKY A, KORTS D: Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled parallel-group study. Neurology (1997) 49:162–168.
   PubMed Web of Science ®Google Scholar
• GUTTMAN M, INTERNATIONAL PRAMIPEXOLE-BROMOCRIPTINE STUDY GROUP: Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced parkinson's disease. Neurology (1997) 49:1060-1065. ••The only comparative trial of pramipexolewith another DA agonists, as well as an important trial evaluating the efficacy and tolerability of pramipexole in advanced PD versus placebo.
   Google Scholar
• PINTER MM, POGARELL 0, OERTEL WH: Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double-blind, placebo-controlled, randomised, multicentre study. J. Neural Neurosurg. Psych. (1999) 66:436–441.
   PubMed Web of Science ®Google Scholar
• MOLHO ES, FACTOR SA, WEINER WJ et al.: The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J. Neural Tranvia Suppl. (1995) 45:225–230.
   PubMedGoogle Scholar
• CLARKE C, SPELLER J: Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database of Systematic Reviews. (2000): Issue 1.
   Google Scholar
• CLARKE C, SPELLER J: Lisuride versus bromocriptime for levodopa-induced complications in Parkinson's disease. Cochrane Database of Systematic Reviews. (2000) Issue 1.
   Google Scholar
• INZELBERG R, CARASSO RL, SCHECHTMAN E, NISIPEANU P: A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease. Clin. Neurapharmacal (2000) 23(5):262–266.
   PubMed Web of Science ®Google Scholar
• PINTER MM, RUTGERS AW, HEBENSTREIT E: An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease. j Neural Trans. (Budapest). (2000) 107(10:1307–1323.
   PubMedGoogle Scholar
• CARRION A, WEINER WJ, SHULMAN LM: A three and a half year experience with pramipexole (PMPX) monotherapy in patients with early parkinson's disease. Neurology (1998) 50(April):A330.
   Google Scholar
• BARONE P: Pramipexole without levodopa as early treatment for Parkinson's disease: long-term follow-up of 717 patients. Neurology (2001) 56\(Suppl. 3):A343.
   Google Scholar
• LAVIGNE GJ, MONTPLAISIR JY: Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep (1994) 17(8):739–743.
   PubMed Web of Science ®Google Scholar
• WALTERS AS: Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov. Disord. (1995) 10(5):634–642.
   Google Scholar
• BRODEUR C, MONTPLAISIR J, GODB OUT R, MARINIER R: Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology (1988) 38(12):1845–1848.
   PubMed Web of Science ®Google Scholar
• WALTERS AS, HENING JW, KAVEY N, CHOKROVERTY S, GIDRO-FRANK S: A double-blind randomised crossover trial of bromocriptine and placebo in restless legs syndrome. Ann. Neural. (1988) 24(3):455–458.
   PubMed Web of Science ®Google Scholar
• WETTER TC, STIASNY K, WINKELMANN J et al.: A randomised controlled study of pergolide in patients with restless legs syndrome. Neurology (1999) 52(5):944–950.
   PubMed Web of Science ®Google Scholar
• REUTER I, ELLIS CM, RAY- CHAUDHURI K: Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neural Scam/. (1999) 100(3):163–167.
   PubMed Web of Science ®Google Scholar
• MONTPLAISIR J, NICOLAS A, DENESLE R, GOMEZ-MANCILLA B: Restless legs syndrome improved by pramipexole: a double-blind randomised trial. Neurology (1999) 52(5):938–943. •A well designed study evaluating the efficacy of pramipexole in RLS.
   Google Scholar
• BECKER PM, ONDO W, SHARON D: Encouraging initial response of restless legs syndrome to pramipexole. Neurology (1998) 51:1221–1223.
   PubMed Web of Science ®Google Scholar
• MONTPLAISIR J, DENESLE R, PETIT D: Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur. Neural (2000) 7\(Suppl. 1):27–31.
   Google Scholar
• STIASNY K, MOLLER JC, OERTEL WH: Safety of pramipexole in patients with restless legs syndrome. Neurology (2000) 55:1589–1590.
   PubMed Web of Science ®Google Scholar
• SIONG-CHI L, KAPLAN J, BURGER CD, FREDRICKSON PA: Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Chi]. Proc. (1998) 73(6)497–500.
   Google Scholar
• SZEGEDI A, WETZEL H, HILLERT A, KLIESER E, GAEBEL W BENKERT 0: Pramipexole, a novel selective dopamine agonist, in major depression. Mac Disord. (1996) 11\(Suppl. 1):266–266.
   Google Scholar
• LECRUBIER Y: A dose-response study of SND 919 vs. haloperidol in the treatment of schizophrenia. Neuropsychapharmacology (1994) 10(Suppl., Part 1):124–124.
   Google Scholar
• WETZEL H, BENKERT 0: Dopamine autoreceptor agonists in the treatment of schizophrenic disorders. Prog. Neuropsycho-pharmacy]. Biol. Psych. (2001) 17(4):525–540.
   Google Scholar
• KASPER S, BARNAS C, HEIDEN A et al:Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. Eur. Neuropsychapharmacal. (1997) 7(1):65–70.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO M: Do dopamine agonists provide neuroprotection? Neurology (1998) 51(2, Suppl. 2):S10–S12.
   Google Scholar
• HALL ED, ANDRUS PK, OOSTVEEN JA, ALTHAUS JS, VON VOIGTLANDER PF: Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against post-ischemic or methamphetamine-induced degeneration of nigrostriatal neurones. Brain Res. (1996) 742(1-2):80–88.
   PubMed Web of Science ®Google Scholar
• CASSARINO DS, FALL CP, SMITH TS, BENNETT JP: Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits mitochondrial permeability transition produced by the parkinsonian neurotoxin methlpyridinium ion. J Neurochem. (1998) 71:295–301.
   PubMed Web of Science ®Google Scholar
• KING DF, COOPER M, SCHAPIRA AH: Pramipexole protects against MPP+ toxicity in SHSy5Y cells be maintaining mitochondrial membrane potential. Neurology (2001) 56\(Suppl. 3):A377–A378.
   Google Scholar
• ZOU L, XU J, JANKOVIC J, APPEL SH, LE W: Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci. Lett. (2000) 281(2-3):167–170.
   PubMed Web of Science ®Google Scholar
• FERGER B, TEISMANN P, MIERAU J: The dopamine agonist pramipexole scavenges hydroxy free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res. (2000) 883(2):216–223.
   PubMed Web of Science ®Google Scholar
• LING ZD, TONG CW, CARVEY PM: Partial purification of a pramipexole-induced trophic activity directed at dopamine neurones in ventral mesencephalic cultures. Brain Res. (1998) 791(1-2):137–145.
   PubMed Web of Science ®Google Scholar
• CARVEY PM, PIERI S, LING ZD: Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. Neural Transm. (Budapest). (1997) 104(2-3):209–228.
   PubMed Web of Science ®Google Scholar
• RINNE UK: Dopamine agonists as primary treatment in Parkinson's disease. Adv. Neural (1987) 45:519–523.
   PubMedGoogle Scholar
• SCHOENBERGER JA: Drug induced orthostatic hypotension. Drug Sal: (1991) 6(6):402–407.
   PubMed Web of Science ®Google Scholar
• SCHILLING JC, ADAMUS WS, PALLUK R: Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Chi]. Pharmacy]. Ther. (1992) 51:541–548.
   PubMed Web of Science ®Google Scholar
• KUJAWA K, LEURGANS S, RAMAN R, BLASUCCI L, GOETZ C: Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch. Neural. (2000) 57(1461):1463–
   Google Scholar
• FRUCHT S, ROGERS JD, GREEN PE, GORDON MF, FAHN S: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 52:1908-1910. •A pivotal, controversial report elucidating the risk of DA agonist-induced sleep attacks in PD.
   Google Scholar
• RYAN M, SLEVIN JT, WELLS A: Non- ergot dopamine agonists induced sleep attacks. Pharmacotherapy (2000) 20(6):724–726.
   PubMed Web of Science ®Google Scholar
• PALS, BHATTACHARYA KF, AGAPITO C, CHAUDHURI KR: A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. I Neural Transm. (Budapest). (2001) 108(1):71–77.
   PubMed Web of Science ®Google Scholar
• FERREIRA JJ, GALITZKY M, MONTASTRUC JL, RASCOL 0: Sleep attacks and Parkinson's disease treatment. Lancet (2000) 355(9212):1333–1334.
   PubMed Web of Science ®Google Scholar
• ANDREU N, CHALE JJ, SENARD JM, THALAMAS C, MONTASTRUC JL, RASCOL 0: L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Chh. Neurapharmacal (1999) 22(1):15–23.
   PubMed Web of Science ®Google Scholar
• HAUSER RA, GAUGER L, ANDERSON WM, ZESIEWICZ TA: Pramipexole-induced somnolence and episodes of daytime sleep. Mov. Disord. (2000) 15(4):658–663.
   PubMed Web of Science ®Google Scholar
• MONTASTRUC JL, RASCOL 0, RASCOL A: A randomised controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3 year follow-up. I Neural Neurosurg. Psych. (1989) 52:773–775.
   PubMed Web of Science ®Google Scholar
• HELY MA, MORRIS JG, REID WG etal.: The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. j Neural Neurosurg. Psych. (1994) 57(8):903–910.
   Google Scholar
• GRAHAM JM, GRUNEWALD RA, SAGAR HJ: Hallucinosis in idiopathic Parkinson's. I Neural Neurosurg. Psych. (1997) 63(4):434–440.
   PubMed Web of Science ®Google Scholar
• SERBY M, ANGRIST B, LIEBERMAN A:Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease. Am. J. Psych. (1978) 135(10):1227–1229.
   PubMed Web of Science ®Google Scholar
• AARSLAND D, LARSEN JP, TANDBERG E, LAAKE K: Predictors of nursing home placement in Parkinson's disease: a population based, prospective study. J. Am. Ceriatr. Soc. (2000) 48(8):938–942.
   Google Scholar
• GOETZ CG, STEBBINS GT: Risk factors for nursing home placement in advanced Parkinson's disease. Neurology (1993) 43(10:2227–2229.
   PubMedGoogle Scholar
• ARNSTEN AF, CAI JX, STEERE JC, GOLDMAN-RAKIC PS: Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. j Neurosci. (1995) 15(5, Part 1):3429–3439.
   Google Scholar
• FRIEDMAN A: Old-onset Parkinson's disease compared with young-onset disease: clinical differences and similarities. Acta Neural Land. (1994) 89(4):258–261.
   PubMed Web of Science ®Google Scholar
• GILADI N, TREVES TA, PALEACU D et al.: Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. j Neural Transm. (Budapest). (2000) 107(1):59–71.
   PubMed Web of Science ®Google Scholar
• QUINN N, ILLAS A, LHERMITTEF, AGID Y: Bromocriptine and domperidone in the treatment of Parkinson's disease. Neurology (1981) 31(6):662–667.
   PubMed Web of Science ®Google Scholar
• CORSINI GU, DEL ZOMPO M, TOCCO E ARCA P, GESSA GL: Drugs acting on dopamine receptors: usefulness of a peripheral blocker in Parkinson's disease. Pharmacy]. Res. Commun. (1980) 12(7):699–707.
   PubMedGoogle Scholar
• TAN E, ONDO W: Clinical characteristics of pramipexole-induced peripheral edema. Arch. Neural. (2000) 57:729–732.
   PubMed Web of Science ®Google Scholar
• OGAWA N: Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease. Neurology (1998) 51(2, Suppl. 2):513–520.
   Google Scholar
• OLANOW CW, WATTS RL, KOLLER WC: An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology (2001) 56 (Suppl. 5):S1–588.
   Google Scholar